S&P 500   4,294.42 (+0.47%)
DOW   33,618.32 (+0.20%)
QQQ   358.54 (+0.99%)
AAPL   171.10 (+0.39%)
MSFT   314.06 (+0.41%)
META   303.06 (+1.79%)
GOOGL   132.64 (+1.61%)
AMZN   126.16 (+0.14%)
TSLA   246.84 (+2.64%)
NVDA   432.30 (+1.79%)
NIO   8.95 (+5.79%)
BABA   85.66 (-0.61%)
AMD   103.01 (+5.04%)
T   14.99 (+0.81%)
F   12.54 (+1.21%)
MU   65.14 (-4.50%)
CGC   0.83 (-6.89%)
GE   112.49 (+1.44%)
DIS   80.09 (+0.24%)
AMC   7.73 (+2.11%)
PFE   32.07 (-0.09%)
PYPL   58.07 (+1.27%)
NFLX   376.50 (-0.29%)
S&P 500   4,294.42 (+0.47%)
DOW   33,618.32 (+0.20%)
QQQ   358.54 (+0.99%)
AAPL   171.10 (+0.39%)
MSFT   314.06 (+0.41%)
META   303.06 (+1.79%)
GOOGL   132.64 (+1.61%)
AMZN   126.16 (+0.14%)
TSLA   246.84 (+2.64%)
NVDA   432.30 (+1.79%)
NIO   8.95 (+5.79%)
BABA   85.66 (-0.61%)
AMD   103.01 (+5.04%)
T   14.99 (+0.81%)
F   12.54 (+1.21%)
MU   65.14 (-4.50%)
CGC   0.83 (-6.89%)
GE   112.49 (+1.44%)
DIS   80.09 (+0.24%)
AMC   7.73 (+2.11%)
PFE   32.07 (-0.09%)
PYPL   58.07 (+1.27%)
NFLX   376.50 (-0.29%)
S&P 500   4,294.42 (+0.47%)
DOW   33,618.32 (+0.20%)
QQQ   358.54 (+0.99%)
AAPL   171.10 (+0.39%)
MSFT   314.06 (+0.41%)
META   303.06 (+1.79%)
GOOGL   132.64 (+1.61%)
AMZN   126.16 (+0.14%)
TSLA   246.84 (+2.64%)
NVDA   432.30 (+1.79%)
NIO   8.95 (+5.79%)
BABA   85.66 (-0.61%)
AMD   103.01 (+5.04%)
T   14.99 (+0.81%)
F   12.54 (+1.21%)
MU   65.14 (-4.50%)
CGC   0.83 (-6.89%)
GE   112.49 (+1.44%)
DIS   80.09 (+0.24%)
AMC   7.73 (+2.11%)
PFE   32.07 (-0.09%)
PYPL   58.07 (+1.27%)
NFLX   376.50 (-0.29%)
S&P 500   4,294.42 (+0.47%)
DOW   33,618.32 (+0.20%)
QQQ   358.54 (+0.99%)
AAPL   171.10 (+0.39%)
MSFT   314.06 (+0.41%)
META   303.06 (+1.79%)
GOOGL   132.64 (+1.61%)
AMZN   126.16 (+0.14%)
TSLA   246.84 (+2.64%)
NVDA   432.30 (+1.79%)
NIO   8.95 (+5.79%)
BABA   85.66 (-0.61%)
AMD   103.01 (+5.04%)
T   14.99 (+0.81%)
F   12.54 (+1.21%)
MU   65.14 (-4.50%)
CGC   0.83 (-6.89%)
GE   112.49 (+1.44%)
DIS   80.09 (+0.24%)
AMC   7.73 (+2.11%)
PFE   32.07 (-0.09%)
PYPL   58.07 (+1.27%)
NFLX   376.50 (-0.29%)
NASDAQ:DICE

DICE Therapeutics (DICE) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$47.55
$47.55
50-Day Range
$46.62
$47.55
52-Week Range
$15.08
$47.90
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$2.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.40

DICE stock logo

About DICE Therapeutics (NASDAQ:DICE) Stock

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.


DICE Stock News Headlines

Wells Fargo Sticks to Their Hold Rating for Incyte (INCY)
What 9 Analyst Ratings Have To Say About DICE Therapeutics
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Lilly Completes Acquisition of DICE Therapeutics
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Lilly Extends Tender Offer To Acquire DICE
Mergers Are Down, but These 2 Sectors Are Booming
Short Volatility Alert: Dice Therapeutics
Needham Downgrades DICE Therapeutics to Hold
Dice Therapeutics (DICE) Receives a New Rating from a Top Analyst
Why DICE Therapeutics Stock Is Soaring Tuesday
See More Headlines
Receive DICE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DICE Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DICE
Fax
N/A
Employees
71
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.40
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+31.2%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$-83,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.13 million
Book Value
$10.86 per share

Miscellaneous

Free Float
45,392,000
Market Cap
$2.27 billion
Optionable
Not Optionable
Beta
1.03
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. J. Kevin Judice Ph.D. (Age 59)
    Founder, CEO & Director
    Comp: $840k
  • Mr. Scott Robertson
    Chief Bus. & Financial Officer
  • Dr. Timothy Lu M.D. (Age 48)
    Ph.D., Chief Medical Officer
    Comp: $700k
  • Dr. John R. Jacobsen Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Mary Riley J.D.
    Gen. Counsel
  • Mr. Venkat Thalladi Ph.D.
    Sr. VP of CMC
  • Mr. Paul Fatheree
    Sr. VP of Medicinal Chemistry













DICE Stock - Frequently Asked Questions

Should I buy or sell DICE Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DICE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DICE, but not buy additional shares or sell existing shares.
View DICE analyst ratings
or view top-rated stocks.

What is DICE Therapeutics' stock price forecast for 2023?

13 brokers have issued 1-year target prices for DICE Therapeutics' stock. Their DICE share price forecasts range from $48.00 to $77.00. On average, they predict the company's stock price to reach $62.40 in the next year. This suggests a possible upside of 31.2% from the stock's current price.
View analysts price targets for DICE
or view top-rated stocks among Wall Street analysts.

When is DICE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our DICE earnings forecast
.

How were DICE Therapeutics' earnings last quarter?

DICE Therapeutics, Inc. (NASDAQ:DICE) posted its earnings results on Tuesday, August, 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.65) by $0.09.

When did DICE Therapeutics IPO?

(DICE) raised $160 million in an initial public offering on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share.

What is DICE Therapeutics' stock symbol?

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

Who are DICE Therapeutics' major shareholders?

DICE Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.06%), Alpine Associates Management Inc. (4.43%), Driehaus Capital Management LLC (4.27%), Braidwell LP (2.16%), KRYGER CAPITAL Ltd (1.85%) and State Street Corp (1.75%). Insiders that own company stock include James Paul Scopa, John R Jacobsen, Kevin Judice, Lu Timothy, Northpond Ventures Gp, Llc, Ra Capital Management, LP, Richard H Scheller and Scott M Robertson.
View institutional ownership trends
.

What is DICE Therapeutics' stock price today?

One share of DICE stock can currently be purchased for approximately $47.55.

How much money does DICE Therapeutics make?

DICE Therapeutics (NASDAQ:DICE) has a market capitalization of $2.27 billion and generates $1.13 million in revenue each year. The company earns $-83,890,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How can I contact DICE Therapeutics?

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.dicemolecules.com. The company can be reached via phone at 650-566-1420 or via email at investors@dicetx.com.

This page (NASDAQ:DICE) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -